<code id='7070311057'></code><style id='7070311057'></style>
    • <acronym id='7070311057'></acronym>
      <center id='7070311057'><center id='7070311057'><tfoot id='7070311057'></tfoot></center><abbr id='7070311057'><dir id='7070311057'><tfoot id='7070311057'></tfoot><noframes id='7070311057'>

    • <optgroup id='7070311057'><strike id='7070311057'><sup id='7070311057'></sup></strike><code id='7070311057'></code></optgroup>
        1. <b id='7070311057'><label id='7070311057'><select id='7070311057'><dt id='7070311057'><span id='7070311057'></span></dt></select></label></b><u id='7070311057'></u>
          <i id='7070311057'><strike id='7070311057'><tt id='7070311057'><pre id='7070311057'></pre></tt></strike></i>

          Home / explore / entertainment

          entertainment


          entertainment

          author:fashion    Page View:17979
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In